TXA 16126
Alternative Names: TXA-16126Latest Information Update: 24 Feb 2026
At a glance
- Originator TAXIS Pharmaceuticals
- Class Antibacterials
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gonorrhoea
- Research Chlamydial infections
Most Recent Events
- 24 Feb 2026 TAXIS Pharmaceuticals has patent protection for TXA 16126 worldwide
- 24 Feb 2026 Early research in Chlamydial infections in USA (PO) before February 2026 (TAXIS Pharmaceuticals pipeline, February 2026)
- 24 Feb 2026 Preclinical trials in Gonorrhoea in USA (PO) before February 2026 (TAXIS Pharmaceuticals pipeline, February 2026)